Atrial-selective sodium channel block for the treatment of atrial fibrillation.
about
AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dogProton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazineEffect of dronedarone on Na+, Ca2+ and HCN channels.Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.Advances in the Pharmacological Treatment of Atrial Fibrillation.Ranolazine: a new approach to treating an old problem.Electrophysiologic basis for the antiarrhythmic actions of ranolazine.Role of RBM25/LUC7L3 in abnormal cardiac sodium channel splicing regulation in human heart failure.Novel pharmacological targets for the rhythm control management of atrial fibrillation.Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalolAtrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.Role of late sodium channel current block in the management of atrial fibrillation.New developments in atrial antiarrhythmic drug therapy.Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications.Atrial selectivity of antiarrhythmic drugs.Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli: Experimental and theoretical analysis.Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.[Basic mechanisms of the new antiarrhythmic drugs in atrial fibrillation].Advances in the Pharmacologic Management of Atrial Fibrillation.Larger late sodium current density as well as greater sensitivities to ATX II and ranolazine in rabbit left atrial than left ventricular myocytes.
P2860
Q24607775-DE597AEA-E185-493F-B3F0-10BB465021EAQ28293492-039D7988-8D68-4AF3-8B97-318E2D946FAFQ33807062-AAA44FE5-A048-4405-B814-B39E941203FAQ34181734-B458974E-0F24-4176-B892-1F92EA3996F5Q34383573-68C8BF07-A640-4D4F-8D07-3B6C14454A80Q34457675-11B8B4C4-F36D-40C9-9609-4BAC5643F0C1Q35091243-8C5FA06B-3394-4DB5-BE0C-9868B7C1DDABQ35210482-BF197F31-7D42-4291-9E81-5D15F49FD38BQ35489060-919C2C9D-DBFA-43AB-AC6B-4A88546991CCQ35650683-B89AD183-8B58-42D5-B7AA-CE30B0B13E58Q35897567-987253B6-2861-473E-B000-B166E902BB76Q36013079-1BD6BC22-460D-437D-93A8-F24E9F551488Q36570112-02481804-312F-4585-BF3A-6C5B4B794C6EQ37697498-D45A6823-042C-4308-815E-17EA7160A489Q37821136-9F33BF68-1A4C-4616-AF18-C0C6B8269B61Q38111636-AE7B9910-AE21-415E-A762-32D9C9F78E5BQ38548311-6D4D2B8A-E9E1-4F4E-BA16-442FC6B18A34Q39760319-BA430607-B4A4-4F86-8EEE-3B6AA30308D2Q41560451-C89355CD-1A03-44A4-B1EC-31DB276AC7EAQ42777572-31598BEF-AF22-4F6C-9938-EC1A75F42E18Q44447235-EE96FF8C-870B-4F3E-BEFA-265163FD0C2F
P2860
Atrial-selective sodium channel block for the treatment of atrial fibrillation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Atrial-selective sodium channel block for the treatment of atrial fibrillation.
@en
Atrial-selective sodium channel block for the treatment of atrial fibrillation.
@nl
type
label
Atrial-selective sodium channel block for the treatment of atrial fibrillation.
@en
Atrial-selective sodium channel block for the treatment of atrial fibrillation.
@nl
prefLabel
Atrial-selective sodium channel block for the treatment of atrial fibrillation.
@en
Atrial-selective sodium channel block for the treatment of atrial fibrillation.
@nl
P2860
P1476
Atrial-selective sodium channel block for the treatment of atrial fibrillation
@en
P2093
Alexander Burashnikov
P2860
P304
P356
10.1517/14728210902997939
P407
P577
2009-06-01T00:00:00Z